Wockhardt Ltd.

is a pharma company with focus on generics and complex injectables, but has seen past regulatory setbacks. ​ It has significant exposure to the UK, US, and emerging markets. ​ Turnaround rests on remediation of plants and new product launches. ​ Risks are high: FDA issues, leverage, and slow growth relative to peers.